The case for & against
Bull & Bear analysis
Bullish
AstraZeneca PLC (NASDAQ: AZN) is a global biopharmaceutical company engaged in the discovery, development, manufacture, and marketing of prescription medicines, particularly for oncology, respiratory, cardiovascular, renal, and metabolic diseases. With a strong focus on innovation and a diverse product pipeline, AstraZeneca aims to address significant unmet medical needs worldwide while maintaining solid commercial performance amidst various market dynamics.
Bull says
- ↑Q2 revenue +6% to $12.5B on strong innovative drug demand.
- ↑YTD 31 regulatory approvals bolster pipeline momentum.
- ↑Core EPS +11% to $7.04, reflecting operational efficiency.
- ↑2026 CapEx +33% to $4.4B for R&D and manufacturing expansion.
- ↑Dividend raised to $3.20/share in 2025, planned $3.30 in 2026.
- ↑Management aims for $80B revenue by 2030 on robust pipeline.
Bear says
- ↓Impending exclusivity losses on key products like Farciga and Brilinta.
- ↓Core gross margin set to decline on biosimilar competition and rising costs.
- ↓Stock shows high volatility, deterring risk-averse investors.
- ↓Net debt ~$30B may limit funding for R&D or acquisitions.
- ↓Elevated short interest signals investor skepticism on outlook.
- ↓China volume-based procurement dampens growth in key emerging market.
Investment themes with AZN
Weight Loss↓ -1.89%
Products and services targeting weight management
LLY · NVO · PFE
Demographics: Elderly Care↓ -0.50%
Services and products for aging population
UCB.BR · JNJ · AZN
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 08-19-2026bullish
Transcript signals
Bull points
- In the first six months of the year, total revenue grew by 11%, driven by continued demand for innovative medicines.
- Core EPS grew 17%, reflecting the importance we place upon investing in our pipeline while driving operating leverage across our company.
- Since our full year results in February, we have achieved 19 regulatory approvals in key regions, and the pace at which we are bringing new medicines to patients around the world continues to accelerate.
Bear points
- As previously stated, we anticipate that the total revenue core gross margin will decline by around 60 to 70 basis points in 2025, driven by factors such as Medicare Part D redesign, Solaris biosimilar competition, and increased profit share related to partnered products.
- note that the Berlinta LOE, Solaris Biosimilar, and products like Flumist are more second-half weighted, and there's uncertainty regarding Forsiga.
- Solaris revenues continued to decline due to the successful conversion to Eltomiris, as well as biosimilar pressure in Europe.
Read full transcript analysis ›